Introduction
============

This study was conducted to investigate the ablative efficacy and safety of sequential intravesical gemcitabine and mitomycin C with mitomycin C alone in refractory non-muscle invasive bladder cancer (NMIBC).

Methods
=======

A total of 219 patients with refractory NMIBC were prospectively enrolled at tertiary academic center over period of Feb 2009-Jan 2012 & followed for next 3 yrs. They were randomly assigned to either of treatment arms: Gentamycin & mitomycin C (group A) or mitomycin C (group B). All patients underwent a 6-week induction regimen followed by a monthly maintenance regimen for one year if they responded to the induction course.

Results
=======

In Group A 98 of 102 & in group B 94 of 96 patients completed the therapy and were evaluated for response while 6 patient left the therapy in between. The therapy was well tolerated in the rest of patients. In group'A' i.e Gentamycin & mitomycin C a total, 82 patients (83.67%) exhibited a complete response to intravesical therapy. In 12.2% (12) patients had biopsy proven recurrence (22±6.16 months). In group 'B' (mitomycin C), 63 (65.60%) patients exhibited a complete response to intravesical therapy, 22 patients (22.9%) showed a partial response. During follow-up, 16 patients (25.3%) developed recurrence within this period. (14.5 +/- 8.26 months).

Conclusions
===========

Chemoresection with sequential intravesical gemcitabine and mitomycin C administration may be a viable option for BCG refractory non-muscle invasive bladder cancer (NMIBC).
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###### 

Detail parameters of both groups.

  Parameters                    Group A          Group B            P value
  ----------------------------- ---------------- ------------------ ---------
  Total patients                102              96                 NS+
  Male                          81               78                 NS+
  Female                        21               19                 NS+
  Age                           65.7±9.8 yrs     63.9±8.9 yrs       NS+
  Mean Duration of follow up    36 months        36 months          
  Mean size of tumor \<2cm      63               58                 NS+
  Mean sixe of tume \>2 cm      39               38                 NS+
  Stage Ta                      60               58                 NS+
  Stage T1                      42               38                 NS+
  Grade 1                       19               17                 NS+
  Grade 2                       63               61                 NS+
  Grade 3                       20               18                 NS+
  Previous treatment with BCG   All              All                
  Aim of complete response      100%             100%               
  Actual complete response      83.67% (82)      65.6% (63)         0.001\*
  Recurrence %                  12.2% (12)       25.3% (16)         0.001\*
  Recurrence                    22±6.16 months   14.5±8.26 months   0.001\*
  Recurrence range in months    8-36 months      4-14 months        

Values are presented as mean (+/- standard devitation)

Group A: Gemcitabine & Mitomycin (MMC+Gentamycin)

Group B: Mitomycin C(MMS)

\*Statistical significance was analyzed by student t-test

+Statistical significance was analyzed by the chi-square test.

###### 

Details of adverse effects of therapy in both groups.

  Parameters          Group A      Group B     P value
  ------------------- ------------ ----------- ---------
  Dysuria             11.7% (12)   7.2% (7)    NS+
  Suprapubic pain     11.7% (12)   9.3% (9)    NS+
  Hematuria           3.9% (4)     3.1% (3)    NS+
  Chemical Cystitis   7.8% (8)     6.25% (6)   NS+
  Local reaction      6.8% (7)     4.16% (4)   NS+
  Skin reaction       5.8% (6)     4.16% (4)   NS+

Group A: Gemcitabine & Mitomycin (MMC+Gentamycin)

Group B: Mitomycin C(MMS)

\*Statistical significance was analyzed by student t-test

+Statistical significance was analyzed by the chi-square test.
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